10-K: Certara Reports Strong Revenue Growth, Narrows Net Loss in 2025

Certara, Inc. announced a 9% increase in total revenues to $418.8 million and significantly reduced its net loss to $1.6 million for the fiscal year ended December 31, 2025, driven by strong demand and strategic acquisitions.

Summary

• Total revenues increased by 9% to $418.8 million for the fiscal year ended December 31, 2025, up from $385.1 million in 2024.
• Net loss significantly narrowed to $1.6 million in 2025, a substantial improvement from a net loss of $12.1 million in 2024 and $55.4 million in 2023.
• Adjusted EBITDA increased to $134.5 million in 2025, compared to $122.0 million in 2024.
• Software revenue grew by 18% to $183.3 million, while services revenue increased by 3% to $235.6 million in 2025.
• Organic revenue growth for 2025 was 6%, excluding the impact of acquisitions.
• Bookings for the full year 2025 reached $482.1 million, an increase from $445.3 million in 2024.
• Net retention rate for 2025 was 105.3%, a slight decrease from 108.8% in 2024.
• The company repurchased 3,368,374 shares of common stock for $42.6 million under its $100 million stock repurchase program, with $57.4 million remaining available as of December 31, 2025.
• Certara continues to integrate AI and machine learning technologies across its product portfolio, including the launch of Certara.AI in 2023 and the next generation of CoAuthor regulatory writing software in 2024.
• Strategic acquisitions in 2023 and 2024, including Chemaxon, Formedix, and Applied BioMath, expanded the company's biosimulation and data management capabilities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting strong revenue growth and a significant reduction in net loss, alongside strategic advancements in AI and acquisitions. However, a slight dip in net retention rate and a very high effective tax rate introduce some caution, preventing a higher score.

Positives

• Total revenues increased by 9% to $418.8 million in 2025, demonstrating solid top-line growth.
• Net loss significantly improved to $1.6 million in 2025, compared to $12.1 million in 2024, indicating enhanced operational efficiency and cost management.
• Adjusted EBITDA grew to $134.5 million in 2025, reflecting improved underlying business performance.
• Software revenue showed robust growth of 18% to $183.3 million, driven by strong demand and customer expansion.
• Full-year bookings increased to $482.1 million, suggesting continued future revenue potential.
• The company's customers have been associated with 90% or more of all novel drug approvals by the FDA from 2014 through 2025, highlighting the effectiveness and regulatory acceptance of its solutions.
• Strategic acquisitions of Chemaxon (2024), Formedix (2023), and Applied BioMath (2023) have expanded the company's market presence and technological capabilities, particularly in drug discovery and QSP.
• Significant investment in R&D, including the introduction of 103 new software applications and upgrades in 2025, and the integration of AI across its product portfolio, positions the company for future innovation.
• The Board approved a $100 million stock repurchase program in April 2025, with $42.6 million executed in 2025, signaling confidence in the company's valuation and commitment to shareholder returns.

Negatives

• The net retention rate slightly decreased to 105.3% in 2025 from 108.8% in 2024, indicating a potential slowdown in expansion within existing customer accounts.
• The effective income tax rate for 2025 was 120.9%, primarily due to non-deductible items and valuation allowances, leading to a significant tax expense despite a reduced net loss.
• Adjusted net income slightly decreased to $70.9 million in 2025 from $72.9 million in 2024, despite revenue growth, suggesting other non-GAAP adjustments had a larger impact.
• Adjusted diluted earnings per share slightly decreased to $0.44 in 2025 from $0.45 in 2024.

Risks

• Deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities or academic institutions could reduce demand for products and services.
• The market for biosimulation products and related services is competitive and highly fragmented, with competition from other software providers, in-house development, and open-source solutions.
• Changes or delays in government regulation, executive action, or administrative decision-making relating to the biopharmaceutical industry could decrease the need for some services.
• Reduction in R&D spending by customers due to lack of funding, economic conditions, or delays in the drug discovery and development process may reduce demand.
• Operational disruptions, funding constraints, and policy changes at the FDA and other government agencies (e.g., workforce reductions, government shutdowns) could adversely affect regulatory activity and business.
• Consolidation within the biopharmaceutical industry may reduce the pool of potential customers or the number of software licenses.
• Continued revenue growth depends on the ability to successfully increase the customer base, expand relationships with existing customers, and enter new markets.
• Dependence on highly qualified personnel and the ability to retain or recruit additional qualified personnel, especially those with advanced degrees, is critical.
• If independent contractors are characterized as employees, the company could be subject to material adverse effects on its business and employment/withholding liabilities.
• Delays or defects in the release of new or enhanced software or other biosimulation tools may result in increased costs, delayed market acceptance, diminished demand, delayed/lost revenue, and liability.
• Issues relating to the implementation, use, and development of AI and machine learning in products and services may result in increased competition, reputational harm, regulatory action, or legal liability.
• If existing customers do not renew software licenses, do not buy additional solutions, or renew at lower prices, business and operating results will suffer.
• Having government customers and receiving government grants subjects the company to risks including early termination, audits, investigations, sanctions, or penalties.
• Regular evaluation of potential acquisitions and other strategic transactions could divert management's attention, result in additional dilution, and disrupt operations.
• The estimated addressable market is subject to inherent challenges and uncertainties, and overestimation could limit future growth opportunities.
• Adverse global economic conditions (e.g., inflation, higher interest rates, recession, trade tensions) could negatively affect business, results of operations, and financial condition.
• Exposure to economic, political, and other risks associated with global operations, including foreign currency exchange rate fluctuations, political unrest, and trade restrictions.
• Failure to comply with trade compliance and economic sanctions laws and regulations could materially adversely affect reputation and results of operations.
• Current and future litigation, including commercial disputes, employment claims, data protection claims, and intellectual property infringement allegations, could be costly and time-consuming.
• Failure to perform services in accordance with contractual requirements, regulatory standards (GLP, GCP, 21 CFR Part 11), and ethical considerations could lead to significant costs or penalties and harm reputation.
• The loss of one or more major customers (top 10 customers accounted for 24% of 2025 revenues) could materially and adversely affect business.
• Bookings might not accurately predict future revenue, and the company might not realize all or any part of the anticipated revenue reflected in bookings.
• Indebtedness could materially adversely affect financial condition and ability to operate, react to changes, or pay debts.
• Impairment of goodwill and other intangible assets may adversely impact future results of operations.
• Ability to use net operating losses (NOLs) and R&D tax credit carryforwards to offset future taxable income may be subject to certain limitations.
• The market price of common stock has been and may continue to be volatile, potentially declining regardless of operating performance.
• Future sales, or the perception of future sales, of common stock by the company or existing stockholders (e.g., Arsenal Capital Partners owning 22.8%) could cause the market price to decline.
• Exclusive forum provisions in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Business may be subject to risks arising from catastrophic events, including natural disasters, war, terrorism, epidemic diseases, pandemics, and public health crises.
• Reliance on third-party providers of cloud-based infrastructure to host software solutions poses risks of disruption, capacity limitations, or interference.
• Cybersecurity measures breaches or unauthorized access to customer or proprietary data could lead to significant liabilities and loss of customer confidence.
• Subject to numerous privacy and data security laws (HIPAA, HITECH, GDPR, UK GDPR, CCPA) and related contractual requirements, with failure to comply causing significant harm.
• Inability to reliably meet data storage and management or other information technology requirements, or technology failures, could harm customer satisfaction and reputation.
• Utilization of third-party open-source software carries risks of non-compliance with license terms, potential litigation, and liability.
• Inability to adequately enforce or defend ownership and use of intellectual property and other proprietary rights.
• Evolving corporate governance and public disclosure regulations and expectations, including with respect to sustainability matters (e.g., EU CSRD, California climate disclosure laws), could expose the company to risks and increased costs.

Future Outlook

Certara plans to continue investing in expanding its solutions, pursuing strategic partnerships and acquisitions, and growing its international footprint. The company expects headcount and total operating expenses to increase over time, driven by investments in scientific talent, sales and marketing, and R&D, particularly in AI integration. Management anticipates further demand for innovation as AI technology advances and believes existing liquidity will be sufficient to fund operations and capital expenditures for the foreseeable future, with income tax expense expected to rise as profitability grows.

Management Comments

• Our goal is to enable the life sciences industry to use data, modeling, and analytics to make better decisions during drug research, development and commercialization to increase productivity rates and vastly reduce development costs.
• Our approach to AI is grounded in our long-standing expertise in mechanistic and empirical modeling. We deploy AI capabilities within validated scientific frameworks and expert-led workflows, rather than as standalone automated systems. This expert-in-the-loop model allows us to leverage native AI capabilities in a manner that is consistent with regulatory expectations for transparency, reproducibility, and explainability.
• While AI can enhance productivity and insight generation, our solutions continue to rely on validated models and expert interpretation to support decision-making in regulated environments.
• We believe we are still in the early stages of a long-term trend that will continue to advance traditional research and development into a technology-driven era of advanced modeling, simulations, analytics that are dramatically enhanced using AI enabled capabilities.
• We remain focused on reducing the cost, time, and probability of failure of clinical trials for our customers so that they may potentially accelerate and lower overall cost of the delivery of future therapies that are needed by patients worldwide.

Industry Context

StockSavvy.ai notes that Certara operates in a high-growth, yet challenging, biopharmaceutical R&D market, where annual spending exceeds $290 billion but over 90% of drug candidates fail. The company's focus on Model-Informed Drug Development (MIDD) and biosimulation directly addresses the industry's need to increase success rates and reduce the average $6.2 billion, 10-15 year cost of developing a new medicine. The increasing adoption of AI and regulatory support, such as the FDA's Project Optimus, creates a favorable environment for Certara's technology-driven solutions. The market remains competitive, with rivals like Mathworks, Dassault Systemes, Ansys, Simulations Plus, and ICON in software, and specialized service providers like Metrum Research, qPharmetra, and Pharmetheus, alongside in-house capabilities of biopharmaceutical companies. Certara's strategy of integrating AI within validated scientific frameworks aims to differentiate it from general-purpose AI tools and point-solution modeling tools.

Comparison to Industry Standards

• Certara's customers have achieved 90% or more of all novel drug approvals by the FDA from 2014 through 2025, significantly outperforming the general industry success rate where over 90% of drug candidates fail.
• The company's biosimulation solutions aim to reduce the average 10-15 years and $6.2 billion cost to develop a new medicine, a critical advantage compared to traditional drug development processes.
• Certara's integration of AI within validated scientific frameworks contrasts with general-purpose AI tools, positioning it to meet regulatory expectations for transparency and reproducibility in drug development, a key differentiator against broader technology companies entering the space.
• The company competes with established players like Mathworks, Dassault Systemes, Ansys, Simulations Plus, and ICON (NONMEM division) in biosimulation software, and specialized service providers such as Metrum Research, qPharmetra, and Pharmetheus, indicating a fragmented but mature competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• No pending or threatened litigation which, individually or in the aggregate, would have a material adverse effect on the consolidated financial statements as of December 31, 2025.

Related Party Transactions

• Arsenal Capital Partners (Arsenal) and its affiliates control approximately 22.8% of outstanding common stock as of December 31, 2025, and maintain the right to nominate up to two board members. This concentration of ownership could influence stockholder approval matters and potentially lead to differing interests from other common stockholders.
• The amended and restated certificate of incorporation allows directors not employed by the company or their affiliates to engage in similar business activities, and Arsenal may pursue acquisition opportunities complementary to Certara's business, which may not be available to Certara.

Stakeholder Impact

• Shareholders: Potential for increased value through stock repurchases and long-term growth from strategic investments and AI integration, but also risks from market volatility, potential dilution from future capital raises, and the influence of major shareholders like Arsenal.
• Employees: Continued investment in scientific talent and R&D, along with competitive compensation packages, aims to attract and retain highly qualified personnel. Management changes, including new CEO and President appointments, could impact organizational structure and culture. Risk of independent contractors being reclassified as employees could affect employment liabilities.
• Customers: Enhanced product offerings and services, particularly with AI integration and acquisitions, aim to improve drug development efficiency and success rates. However, delays or defects in software, changes in regulatory landscape, or reductions in R&D spending by customers could negatively impact relationships and demand.
• Suppliers/Creditors: The company's indebtedness and ability to generate sufficient cash flow from operations are critical for meeting obligations. Reliance on third-party cloud providers creates dependency risks.
• Regulatory Authorities: Continued collaboration and compliance with regulatory standards (e.g., FDA, EMA) are essential for the company's business model, with changes in regulations or operational disruptions at agencies posing risks.

Next Steps

• Continue to invest in expanding the breadth and depth of solutions, including through acquisitions and international expansion.
• Focus on enhancing modeling productivity, improving data connectivity across the platform, and supporting scientific decision-making through AI investments.
• Actively engage with existing customers to upand cross-sell solutions and facilitate customer growth through higher adoption of biosimulation.
• Attract and hire specialized talent and acquire complementary businesses as new scientific research and technologies arise.
• Monitor and adapt to evolving corporate governance and public disclosure regulations, including those related to sustainability matters (e.g., EU CSRD, California climate disclosure laws).

Key Dates

Recommendation

Certara demonstrates solid revenue growth and a significant reduction in net loss, indicating operational improvements and strategic success in a critical industry. The company's aggressive pursuit of AI integration and strategic acquisitions positions it well for future innovation and market leadership in biosimulation. However, the slight decrease in net retention rate and a notably high effective tax rate in 2025 present areas of concern. The inherent risks associated with a highly competitive market, regulatory changes, and dependence on R&D spending by customers warrant a cautious approach. While the long-term outlook is promising due to its market position and innovation, these factors suggest a 'hold' recommendation for a seasoned investor, allowing for further observation of sustained improvements in profitability metrics and the impact of AI integration on market share and financial performance.

Keywords

Biosimulation, Drug Development, Pharmaceutical R&D, AI in Pharma, Machine Learning, Regulatory Science, Pharmacometrics, Clinical Trials, Software as a Service, Healthcare Technology, Certara, 10-K, Financial Results, Acquisitions, Corporate Governance